Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Anti-Parkinson Drugs Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Dopaminergic
    • 1.4.3 Dopamine Agonists
    • 1.4.4 Enzyme Inhibitors
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Anti-Parkinson Drugs Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital Pharmacy
    • 1.5.3 Retail Pharmacy
    • 1.5.4 Online Stores
  • 1.6 Coronavirus Disease 2019 (Covid-19): Anti-Parkinson Drugs Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Anti-Parkinson Drugs Industry
      • 1.6.1.1 Anti-Parkinson Drugs Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Anti-Parkinson Drugs Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Anti-Parkinson Drugs Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Anti-Parkinson Drugs Market Perspective (2015-2026)
  • 2.2 Anti-Parkinson Drugs Growth Trends by Regions
    • 2.2.1 Anti-Parkinson Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Anti-Parkinson Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Anti-Parkinson Drugs Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Anti-Parkinson Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Anti-Parkinson Drugs Players by Market Size
    • 3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Anti-Parkinson Drugs Market Concentration Ratio
    • 3.2.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2019
  • 3.3 Anti-Parkinson Drugs Key Players Head office and Area Served
  • 3.4 Key Players Anti-Parkinson Drugs Product Solution and Service
  • 3.5 Date of Enter into Anti-Parkinson Drugs Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2021-2026)

5 Anti-Parkinson Drugs Breakdown Data by Application (2015-2026)

  • 5.1 Global Anti-Parkinson Drugs Market Size by Application (2015-2020)
  • 5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Anti-Parkinson Drugs Market Size (2015-2020)
  • 6.2 Anti-Parkinson Drugs Key Players in North America (2019-2020)
  • 6.3 North America Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 6.4 North America Anti-Parkinson Drugs Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Anti-Parkinson Drugs Market Size (2015-2020)
  • 7.2 Anti-Parkinson Drugs Key Players in Europe (2019-2020)
  • 7.3 Europe Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 7.4 Europe Anti-Parkinson Drugs Market Size by Application (2015-2020)

8 China

  • 8.1 China Anti-Parkinson Drugs Market Size (2015-2020)
  • 8.2 Anti-Parkinson Drugs Key Players in China (2019-2020)
  • 8.3 China Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 8.4 China Anti-Parkinson Drugs Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Anti-Parkinson Drugs Market Size (2015-2020)
  • 9.2 Anti-Parkinson Drugs Key Players in Japan (2019-2020)
  • 9.3 Japan Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 9.4 Japan Anti-Parkinson Drugs Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Anti-Parkinson Drugs Market Size (2015-2020)
  • 10.2 Anti-Parkinson Drugs Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Anti-Parkinson Drugs Market Size by Application (2015-2020)

11 India

  • 11.1 India Anti-Parkinson Drugs Market Size (2015-2020)
  • 11.2 Anti-Parkinson Drugs Key Players in India (2019-2020)
  • 11.3 India Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 11.4 India Anti-Parkinson Drugs Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Anti-Parkinson Drugs Market Size (2015-2020)
  • 12.2 Anti-Parkinson Drugs Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Anti-Parkinson Drugs Market Size by Type (2015-2020)
  • 12.4 Central & South America Anti-Parkinson Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 AbbVie
    • 13.1.1 AbbVie Company Details
    • 13.1.2 AbbVie Business Overview and Its Total Revenue
    • 13.1.3 AbbVie Anti-Parkinson Drugs Introduction
    • 13.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2015-2020))
    • 13.1.5 AbbVie Recent Development
  • 13.2 Mylan Laboratories
    • 13.2.1 Mylan Laboratories Company Details
    • 13.2.2 Mylan Laboratories Business Overview and Its Total Revenue
    • 13.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
    • 13.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.2.5 Mylan Laboratories Recent Development
  • 13.3 Valeant Pharmaceuticals
    • 13.3.1 Valeant Pharmaceuticals Company Details
    • 13.3.2 Valeant Pharmaceuticals Business Overview and Its Total Revenue
    • 13.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
    • 13.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.3.5 Valeant Pharmaceuticals Recent Development
  • 13.4 Novartis
    • 13.4.1 Novartis Company Details
    • 13.4.2 Novartis Business Overview and Its Total Revenue
    • 13.4.3 Novartis Anti-Parkinson Drugs Introduction
    • 13.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.4.5 Novartis Recent Development
  • 13.5 GlaxoSmithKline
    • 13.5.1 GlaxoSmithKline Company Details
    • 13.5.2 GlaxoSmithKline Business Overview and Its Total Revenue
    • 13.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
    • 13.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.5.5 GlaxoSmithKline Recent Development
  • 13.6 Zambon Pharmaceuticals
    • 13.6.1 Zambon Pharmaceuticals Company Details
    • 13.6.2 Zambon Pharmaceuticals Business Overview and Its Total Revenue
    • 13.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
    • 13.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.6.5 Zambon Pharmaceuticals Recent Development
  • 13.7 Pfizer, Inc.
    • 13.7.1 Pfizer, Inc. Company Details
    • 13.7.2 Pfizer, Inc. Business Overview and Its Total Revenue
    • 13.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
    • 13.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.7.5 Pfizer, Inc. Recent Development
  • 13.8 Hoffmann-La Roche
    • 13.8.1 Hoffmann-La Roche Company Details
    • 13.8.2 Hoffmann-La Roche Business Overview and Its Total Revenue
    • 13.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
    • 13.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.8.5 Hoffmann-La Roche Recent Development
  • 13.9 Merck & Co.
    • 13.9.1 Merck & Co. Company Details
    • 13.9.2 Merck & Co. Business Overview and Its Total Revenue
    • 13.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
    • 13.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.9.5 Merck & Co. Recent Development
  • 13.10 Orion Pharma
    • 13.10.1 Orion Pharma Company Details
    • 13.10.2 Orion Pharma Business Overview and Its Total Revenue
    • 13.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
    • 13.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 13.10.5 Orion Pharma Recent Development
  • 13.11 UCB
    • 10.11.1 UCB Company Details
    • 10.11.2 UCB Business Overview and Its Total Revenue
    • 10.11.3 UCB Anti-Parkinson Drugs Introduction
    • 10.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 10.11.5 UCB Recent Development
  • 13.12 Teva Pharmaceutical Industries Ltd.
    • 10.12.1 Teva Pharmaceutical Industries Ltd. Company Details
    • 10.12.2 Teva Pharmaceutical Industries Ltd. Business Overview and Its Total Revenue
    • 10.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
    • 10.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 10.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
  • 13.13 Vertical Pharmaceuticals, LLC
    • 10.13.1 Vertical Pharmaceuticals, LLC Company Details
    • 10.13.2 Vertical Pharmaceuticals, LLC Business Overview and Its Total Revenue
    • 10.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
    • 10.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 10.13.5 Vertical Pharmaceuticals, LLC Recent Development
  • 13.14 ACADIA Pharmaceuticals Inc.
    • 10.14.1 ACADIA Pharmaceuticals Inc. Company Details
    • 10.14.2 ACADIA Pharmaceuticals Inc. Business Overview and Its Total Revenue
    • 10.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
    • 10.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2015-2020)
    • 10.14.5 ACADIA Pharmaceuticals Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Anti-Parkinson Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Anti-Parkinson Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    AbbVie
    Mylan Laboratories
    Valeant Pharmaceuticals
    Novartis
    GlaxoSmithKline
    Zambon Pharmaceuticals
    Pfizer, Inc.
    Hoffmann-La Roche
    Merck & Co.
    Orion Pharma
    UCB
    Teva Pharmaceutical Industries Ltd.
    Vertical Pharmaceuticals, LLC
    ACADIA Pharmaceuticals Inc.

    Market segment by Type, the product can be split into
    Dopaminergic
    Dopamine Agonists
    Enzyme Inhibitors
    Others
    Market segment by Application, split into
    Hospital Pharmacy
    Retail Pharmacy
    Online Stores

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Anti-Parkinson Drugs status, future forecast, growth opportunity, key market and key players.
    To present the Anti-Parkinson Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Anti-Parkinson Drugs are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now